Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

771
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
771
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

439
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
439
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

483
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
483
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

2.7K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
2.7K
Nervous Tissue: Myelin01:25

Nervous Tissue: Myelin

6.2K
The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
6.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus Definitions of Disease Activity and Clinical Outcomes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Neurology·2026
Same author

Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial.

Therapeutic advances in neurological disorders·2026
Same author

Insight in the Unmet Needs Encountered During the Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Journal of the peripheral nervous system : JPNS·2025
Same author

Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.

Expert review of clinical immunology·2025
Same author

Feasibility and Reliability of a Monitoring App for Chronic Inflammatory Neuropathies.

Journal of the peripheral nervous system : JPNS·2025
Same author

Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling.

Journal of the peripheral nervous system : JPNS·2025
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Feb 21, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

4.9K

Chronic Demyelinating Polyneuropathies.

Jeffrey A Allen

    Continuum (Minneapolis, Minn.)
    |October 3, 2017
    PubMed
    Summary
    This summary is machine-generated.

    This review covers chronic demyelinating neuropathies, emphasizing immune-mediated conditions. Accurate diagnosis and tailored treatments are crucial due to the heterogeneity of these peripheral nerve disorders.

    More Related Videos

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.1K
    Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
    08:57

    Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

    Published on: March 26, 2015

    27.8K

    Related Experiment Videos

    Last Updated: Feb 21, 2026

    A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
    04:55

    A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

    Published on: May 11, 2022

    4.9K
    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
    09:41

    Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

    Published on: July 19, 2019

    12.1K
    Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
    08:57

    Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

    Published on: March 26, 2015

    27.8K

    Area of Science:

    • Neurology
    • Immunology
    • Peripheral Nerve Disorders

    Background:

    • Chronic demyelinating neuropathies encompass a heterogeneous group of peripheral nerve disorders.
    • Differentiating immune-mediated neuropathies from other causes is clinically significant.

    Purpose of the Study:

    • To review chronic demyelinating neuropathies.
    • To focus on the diagnosis and treatment of immune-mediated neuropathies.
    • To identify features distinguishing immune-mediated from other demyelinating conditions.

    Main Methods:

    • Literature review of chronic demyelinating neuropathies.
    • Analysis of diagnostic and treatment strategies for immune-mediated neuropathies.
    • Comparison of clinical and pathological features.

    Main Results:

    • Advances in phenotyping and outcomes assessment improve disease recognition and monitoring.
    • Evolving understanding of immunopathogenesis.
    • New antibody identification and recognition of early pathogenic features like node of Ranvier dysfunction may lead to advancements.

    Conclusions:

    • Chronic demyelinating polyneuropathies are diverse with overlapping features.
    • Variability in pathogenesis, treatment, and prognosis necessitates accurate diagnosis.
    • Disease-specific treatment approaches are essential for optimal patient outcomes.